Startups Directory

Thanks to plant-based biotechnologies and a licensing-based model, Serendip Innovations helps therapeutic asset developers design better products, safer and easier to manufacture.

Technical limitations of conventional vectors (modified antibodies, viral vectors and lipid nanoparticles) around instability, immunogenicity, cell targeting, manufacturing, etc.

Better pharmaceutical products, better impact on patients

2,700,000 €

3,000,000 €

Limbium is a health-tech startup transforming upper-limb prosthetics through advanced engineering, digital manufacturing and full personalization. We design and produce three types of prosthetic solutions (bionic, sports and biomechanical) all lightweight, functional and tailored to each user. Our products are 100% publicly subsidized in Spain, making high-quality prosthetics accessible to everyone. As the only manufacturer of upper-limb sports prostheses in Europe, we combine patented technology with a fast, affordable and user-centric workflow. Our mission is to empower people with limb differences to regain independence, performance and quality of life.

Our technology solves the main barriers in upper-limb prosthetics: high costs, long delivery times, lack of personalization and limited access to high-quality devices. Traditional prostheses are expensive, heavy and often poorly adapted to each user. Limbium combines advanced engineering, digital manufacturing and customizable designs to deliver lightweight, functional and affordable prosthetic solutions (including bionic, sports and biomechanical models) fully tailored to each patient. We make high-performance prosthetics accessible, reducing inequalities and improving autonomy and quality of life.

Our technology generates a strong social impact by making high-quality upper-limb prosthetics accessible to everyone, regardless of income or location. By reducing costs, personalizing each device and shortening delivery times, we help people with limb differences regain independence, mobility and confidence. This leads to better health outcomes, improved employability and greater participation in social and sport activities. Additionally, our sports prostheses promote inclusion in athletics, enabling amputees to compete, train and perform at a higher level. Ultimately, Limbium reduces inequalities and enhances quality of life at scale

N/A

N/A

MiWEndo is a medical technology startup transforming colorectal cancer prevention with a microwave imaging and AI system that detects lesions invisible to standard colonoscopy. Our device provides functional, 360° information beyond optical imaging, enabling higher detection rates. We operate under a razor-and-blade model with strong clinical traction and a clear path to CE marking.

Colorectal cancer is highly preventable, but colonoscopy still misses up to 22% of dangerous polyps because many lesions remain invisible: too flat, too low-contrast, or hidden behind folds. Even advanced optical AI cannot detect what the camera cannot see. This leads to interval cancers, unnecessary procedures, and higher costs for healthcare systems. MiWEndo solves this by adding microwave imaging to colonoscopy, capturing functional tissue information and detecting lesions outside the optical field of view, significantly improving detection and enabling more accurate, real-time diagnosis.

MiWEndo enables a safer and more reliable colonoscopy by detecting flat, hidden and low-contrast polyps that currently go unnoticed. This directly reduces preventable colorectal cancers and enables earlier, more accurate decision-making. Patients benefit from fewer complications, fewer unnecessary resections and earlier treatment when needed. Hospitals benefit from improved diagnostic efficiency and reduced downstream costs. At a population level, it contributes to more effective screening programs and a significant public-health impact through better prevention.

€1.5M

€5M

Mential is a precision mental health company building an AI-driven Digital Twin platform that transforms how psychological care is delivered at scale. Using multimodal data (text, voice, behaviour and context) structured into clinically validated FHIR markers, Mential enables continuous monitoring, early risk detection and personalised micro-interventions between sessions. Designed for hospitals, insurers and enterprise health providers, the platform reduces clinician workload, improves outcomes and lowers costs while remaining fully interoperable and aligned with emerging EU regulation.

Mential addresses the structural failures of current mental health care, not just access or content gaps. Specifically, it solves: 1. Episodic and reactive care Mental health treatment today is based on infrequent sessions and retrospective self-reporting. Between sessions, patients are not monitored and deterioration goes unnoticed. Mential enables continuous, real-time monitoring through a digital twin, allowing early detection of risk and timely intervention. 2. Lack of personalisation and low effectiveness Over 50% of patients do not respond to first-line psychological treatment. Existing digital solutions are largely static and symptom-based. Mential uses multimodal AI and structured clinical markers to personalise interventions dynamically, improving outcomes and adherence. 3. Severe clinician shortage and poor scalability Traditional therapy scales linearly with clinicians, creating long waiting lists and high costs. Mential automates 80–90% of supervision and monitoring tasks, enabling one clinician to safely supervise hundreds of patients, dramatically increasing capacity. 4. Fragmented, unstructured clinical data Mental health data is mostly qualitative, siloed and non-interoperable, limiting clinical insight and system-level learning. Mential converts behavioural and emotional signals into standardised, FHIR-native clinical data, making mental health measurable, auditable and interoperable. 5. Rising costs for insurers, hospitals and employers Mental health is one of the fastest-growing cost drivers due to chronicity, relapse and late intervention. By enabling early detection, continuous care and more efficient use of clinicians, Mential reduces treatment costs, relapses and high-cost crisis events. In short, Mential solves the problem of ineffective, non-scalable and data-poor mental health care, replacing it with a continuous, personalised and scalable precision mental health model suitable for real healthcare systems.

Mential transforms mental health care from a reactive, appointment-based system into a continuous, preventive and scalable model. It enables earlier support, reduces relapses and makes mental health measurable and manageable at population level. This shift benefits citizens through faster access and better outcomes, women through tailored care for underserved life stages, clinicians by reducing overload and burnout, and health systems and insurers by lowering long-term costs and improving sustainability. At scale, Mential helps societies address one of their biggest health challenges with a fairer, more efficient and more resilient care model.

400.000€

500.000€

Spin-off biotecnológica de ICO-IDIBELL centrada en el desarrollo de una nueva terapia contra un mecanismo de resistencia en cáncer colorrectal avanzado, combinada con un biomarcador de selección de pacientes, con modelo de negocio basado en licencias a grandes farmacéuticas y servicios de I+D/consultoría en oncología.

Cancer resistance

National health system

€1M

€4M

Processing/Management/Valorization of farming manure, slurry, and whey from cheese making

Prevent contamination by better management of manure, slurry, and whey from cheese preparation

Reducing contamination and minimizing explotation of mineral resources to fertilize crops

€500.000

€500.000

NeuroshedBio is a Madrid-based platform company that generates next-generation human brain organoids from SHED (stem cells derived from exfoliated baby teeth) to accelerate neuroscience R&D. Our proprietary technology preserves each child’s genetic and epigenetic identity, enabling physiologically relevant models of neurodevelopmental disorders.

NeuroshedBio reduces risk and cost in neuroscience drug development by providing scalable, patient-specific human organoids and integrated analytics that far outperform existing animal and iPSC-based models.

NeuroshedBio accelerates the arrival of effective neurological treatments, advances precision medicine, and reduces the economic and ethical costs associated with current preclinical models of neurodevelopmental disorders .

€150K

NeuroshedBio is raising a €0.75M–€1.2M pre-seed round to validate our organoid platform, achieve our first pharma pilot, and build 18–24 months of runway toward a Seed round

Synthetic Data generation to optimize Clinical Trials

The clinical trials market needs to find tools that enable it to reduce the time and cost of its trials, as a complete study involves an average investment of €50 million and takes between 10 and 15 years, with more than 70% of them ending in failure. In addition, both the industry and regulatory agencies are constantly seeking solutions to reduce the number of patients put at risk in clinical trials, mainly in control groups. Synthetrial has developed an algorithm, based on generative AI, that generates highly reliable synthetic data that maintains clinical evidence. From a small sample of patients recruited in a trial, the Synthetrial model generates virtual patients, allowing trial simulations to be carried out. This totally disruptive technology reduces the time and cost of a trial, detects those with a high probability of failure and minimises risks to patients.

Synthetrial's activity focuses on generating a positive and measurable impact on the healthcare system and society. The lack of representativeness in clinical, healthcare and cosmetic trials is a barrier to the development of effective and fair treatments. Synthetrial has a major social impact, targeting patients suffering from different diseases who take risks by participating in clinical trials that are likely to fail, or who do not even have access to innovative treatments because they belong to minority populations (rare diseases, pregnant women, paediatric patients, elderly people, etc.). The solution proposed by Synthetrial allows for the simulation of data from underrepresented patients, thereby contributing to more equitable access to biomedical innovation. Furthermore, by reducing the need for real data, it enables research in contexts where data is scarce. For example, data from pregnant women, a group systematically excluded for ethical reasons, can be simulated, facilitating the development of safe treatments without putting real people at risk. Pilots are also being conducted focusing on neurodegenerative diseases in older people, where recruitment difficulties limit clinical evidence. The technology also makes it possible to create synthetic histories of rare diseases, increasing the visibility and understanding of little-known pathologies, which can improve diagnosis, monitoring and treatment.

150.000 €

300.000 €

Developing therapies for unmet needs in oncology

Therapeutics unmet needs

Improving clinical outcome of patiens

500.000 EUR

1 million EUR

eB 2 develops solutions for the management and improvement of mental health, emotional well-being, and occupational health through Artificial Intelligence and mobile technologies. We harness the power of Artificial Intelligence for mental health and emotional well-being. We transform data into actionable knowledge for healthcare professionals, clinical researchers, and academics.

Mental disorders affect one in six Europeans and cost over €600 billion annually. Most begin early, become chronic, and remain underdiagnosed or poorly monitored due to fragmented care and lack of objective tools. eB2 MindCare addresses this gap by combining passive behavioral data with explainable AI algorithms that detect early signs of deterioration and support clinical decisions. In ongoing studies, the system achieves a 50 % reduction in suicide attempts, demonstrating its transformative potential.

eB2 MindCare directly addresses one of Europe’s most urgent social and health challenges: mental disorders affecting one in six citizens and costing over €600 billion annually. By enabling continuous, AI-driven mental-health monitoring, the platform supports early detection, prevention, and intervention, reducing crisis episodes, hospital readmissions, and suicide risk.

1,000,000€

BioEclosion’s patented magneto-actuated device integrates disposable magnetic-cartridge immunoassays with electrochemical readout to deliver lab-quality, quantitative results from a single drop of whole blood in about 10 minutes on a smartphone, enabling end-users to take immediate action at the point of need.

Our technology tackles the lack of fast, accessible, lab-quality testing at the point of need. Currently, immunoassay diagnostics for infections and biomarkers often require central laboratories, expensive equipment, trained personnel, and long turnaround times, which delay clinical decisions and are frequently unavailable in rural or low-resource settings. Existing point-of-care tests are often qualitative or low sensitivity, limiting their use for monitoring disease evolution or treatment response.

Our technology will have a positive impact on society by making high-quality diagnostics more accessible, affordable, and integrated across sectors. Human health, veterinary diagnostics, food safety, and environmental control typically rely on separate, non-interoperable platforms, increasing cost and complexity. BioEclosion’s magneto-actuated device addresses this by offering a single, portable, quantitative, and easy-to-use platform that delivers rapid, reliable results from a small sample directly on a smartphone. This will enable earlier and more accurate clinical decisions, better monitoring of animal health, faster detection of contaminants in food and water, and improved environmental surveillance. Ultimately, it supports a One Health approach, strengthens outbreak preparedness, reduces inequalities in access to diagnostics (especially in low-resource settings), and improves overall public health and safety.

1M€

2.2M€

From Empirical to Digital At OPTICmizing, we digitalize and automate food industry processes traditionally managed by experience. Using advanced optical sensors and intelligent models, we turn data into precise, automatic decisions. We optimize every production stage—from raw material selection to packaging—enhancing quality, standardizing processes, and reducing costs, waste, and energy use. With our Industry 4.0 solutions, clients achieve more efficient, sustainable, and profitable operations. At OPTICmizing, vision and technology modernize the food industry.

Manual food processes to digital and optimal

Less costs for industry, better prices for consumers. Also safer products in some cases...

300.000€

300.000€

Loomee Health is the copilot for mental health professionals, empowering them with explainable clinical intelligence. Our comprehensive platform combines management, evidence-based resources, and AI-powered monitoring to optimize intervention and decision-making.

We are experiencing a global mental health crisis. In Spain, the situation is critical: with only 6 psychologists per 100,000 inhabitants (the European average is 18), 40% of patients wait months for care. Furthermore, professionals dedicate almost 40% of their time to administrative tasks, and their treatments have low adherence (50%) and a high dropout rate (40%).

Loomee has a positive impact, not only by providing the professional with 1 hour a day and improving the patient's quality of life (+15% adherence, -20% symptom reduction, -25% treatment duration), but also (potentially) reducing more than €900M in indirect costs for the public sector

€500.000

€500.000

Automate the operations carried out by pest control companies to monitor and surveil insects that transmit diseases.

We have developed an innovative sensor that activates upon detecting the presence of an insect. This sensor sends an alert to a centralized platform, providing crucial information, including the exact date and time of the sighting, a picture of the insect in question, and data on environmental conditions such as temperature and humidity at that moment. This revolutionary technological solution has a direct impact on one of the major challenges facing pest control companies: labor costs. Our product offers a more efficient way to monitor and address pest issues, as it eliminates the need for periodic manual inspections. This not only saves time but also reduces the costs associated with employing personnel to perform these repetitive tasks. Furthermore, by providing detailed data about the environment in which the insect was detected, our sensor enables pest control companies to make more informed and specific decisions on how to address the situation.

We directly impact the use and handling of pesticides for pest control.

€135K

€150k

Horux Medical is a virtual university focused on healthcare areas that serves as a VR meeting point between students and experts physically located in different parts of the world. The instructor can design their rooms interactively by uploading their own anatomical models, marking regions of interest on them, and using basic scripting to record actions within the VR. The rooms configurable by the expert can be both theoretical and practical.

We bring expert knowledge closer to other experts or students through the creation of a VR university where the rooms are fully configurable. Our intention is to allow any student to enjoy quality education regardless of their physical location.

We enable any student or expert to share knowledge about a specific health area regardless of physical distance.

100,000 €

100,000 €